Lv5
1250 积分 2024-02-21 加入
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
1小时前
已完结
Role of Protein Kinases in Cellular Signaling
9天前
已完结
Mechanisms of cutaneous toxicities to EGFR inhibitors
2个月前
已完结
Rational design of inhibitors that bind to inactive kinase conformations
2个月前
已关闭
Kinase inhibitors: the road ahead
2个月前
已完结
Protein kinases — the major drug targets of the twenty-first century?
2个月前
已完结
Oncogenic kinase signalling
3个月前
已完结
Development and testing of a general amber force field
3个月前
已完结
Alchemical Transformations and Beyond: Recent Advances and Real-World Applications of Free Energy Calculations in Drug Discovery
3个月前
已完结
Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations
3个月前
已完结
皖公网安备34019202002308
